<DOC>
	<DOC>NCT00047788</DOC>
	<brief_summary>The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study</brief_summary>
	<brief_title>Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Confirmed diagnosis of multiple myeloma. Patients must have a minimum serum Mprotein level &gt;=10g/L on serum protein electrophoresis or for patients with light chain only disease, a minimum BenceJones protein of 1g/24 hr. Patients must have received prior treatment for multiple myeloma: patients may have received 1 or 2 prior regimens of oral alkylating based chemotherapy and must have relapsed following treatment (&gt;= 3 months) OR patients may have relapsed following high dose chemotherapy and SCT as first line treatment provided they have not had any other treatment. Lab at inclusion of AGC &gt;= 1.0 x10_9/L and platelets &gt;= 50 x10_9/L Bilirubin, AST and/or ALT &lt;= 1.5 x UNL; creatinine &lt; 2 x UNL, Potassium &gt;= 4.0 mmol/L; calcium and magnesium within normal limitsÂ· Patients may not have had &gt; 2 prior regimens of chemotherapy and/or prior thalidomide treatment. Patients may not have had any nonalkylating based chemotherapy. Patients with a history of other malignancies, except: adequately treated nonmelanoma skin cancer, curatively treated insitu cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for &gt;= 5 years. Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test within 7 days prior to registration and must be using effective contraception throughout the study. Patients who have relapsed during treatment with oral alkylating chemotherapy. Patients who have received more than 2 prior regimens of chemotherapy. Patients who have received excluded medication or have excluded medical conditions. Patients who have received any nonalkylating based chemotherapy regimens as initial therapy, or as therapy for recurrent disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Relapsed Multiple Myeloma</keyword>
</DOC>